Across the recent three months, 6 analysts have shared their insights on Abbott Laboratories ABT, expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 3 | 1 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 1 | 1 | 0 | 0 | 0 |
2M Ago | 1 | 1 | 0 | 0 | 0 |
3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $126.83, with a high estimate of $143.00 and a low estimate of $120.00. This current average has increased by 2.95% from the previous average price target of $123.20.
Exploring Analyst Ratings: An In-Depth Overview
A comprehensive examination of how financial experts perceive Abbott Laboratories is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Raj Denhoy | Jefferies | Maintains | Hold | $120.00 | $120.00 |
Adam Maeder | Piper Sandler | Announces | Overweight | $131.00 | - |
Raj Denhoy | Jefferies | Raises | Buy | $120.00 | $112.00 |
Joanna Wiensch | Citigroup | Raises | Buy | $127.00 | $119.00 |
Matt Miksic | Barclays | Raises | Overweight | $143.00 | $140.00 |
Vijay Kumar | Evercore ISI Group | Lowers | Outperform | $120.00 | $125.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Abbott Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Abbott Laboratories compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Abbott Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Abbott Laboratories's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Abbott Laboratories analyst ratings.
Get to Know Abbott Laboratories Better
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Breaking Down Abbott Laboratories's Financial Performance
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Abbott Laboratories's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 4.0%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Abbott Laboratories's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.55% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Abbott Laboratories's ROE excels beyond industry benchmarks, reaching 3.33%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Abbott Laboratories's ROA excels beyond industry benchmarks, reaching 1.79%. This signifies efficient management of assets and strong financial health.
Debt Management: Abbott Laboratories's debt-to-equity ratio is below the industry average. With a ratio of 0.38, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.